CCS
LUMO

Crosspoint Capital Strategies’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Crosspoint Capital Strategies’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15
Closed -$7K – 654
2015
Q1 		$7K Buy
+15
New +$5.81K ﹤0.01% 413
2014
Q1 		– Sell
-29
Closed -$10K – 677
2013
Q4 		$10K Buy
+29
New +$5.16K ﹤0.01% 435

Other funds holding LUMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Crosspoint Capital Strategies's LUMO Position: Q2 2015 in Review

Crosspoint Capital Strategies sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2015, closing a stake of 15 shares — an estimated $7K sold.

Crosspoint Capital Strategies first reported a position in LUMO in Q4 2013 and held it in 2 quarters. The position peaked at $10K in Q4 2013. 145 funds tracked by Wall St. Rank hold LUMO as of Q2 2015.

  • Crosspoint Capital Strategies reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 15 Lumos Pharma, Inc. Common Stock shares in Q2 2015, an estimated $7K.
  • Crosspoint Capital Strategies first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 2 quarters.
  • Crosspoint Capital Strategies's Lumos Pharma, Inc. Common Stock position peaked at $10K in Q4 2013.
  • 145 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2015, filed 24 Aug 2015.